Advertisement

HIV JournalView
  

HIV JournalView


  • No Excess Death Among HIV-Infected People -- as Long as CD4+ Cell Counts Are Kept Close to Normal (March 15, 2013)
    A new study gives us the most conclusive evidence to date that HIV-infected people who adhere to therapy and keep their CD4+ cell count above 500 are just as healthy overall as HIV-uninfected people.
    In HIV JournalView, from TheBodyPRO.com
  • Dangers of Smoking Greatly Enhanced for HIV-Infected Patients, Study Finds (February 21, 2013)
    A recently published study from a national cohort of HIV-infected Danes supplies a bunch of new facts that you can use to scare -- er, counsel -- your patients afflicted with tobaccoism.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Clinical Developments of 2012 (December 2012)
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView: October/November 2012 (November 27, 2012)
    David Alain Wohl, M.D., looks at new findings regarding racial disparities in HIV care, predicting hospital readmissions, sexual transmission of HCV, treatment of diabetes, and more accurate/efficient ways to measure and predict adherence.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView: September 2012 (October 15, 2012)
    David Alain Wohl, M.D., explores recently published findings regarding access to HIV care in the U.S., the impact of pain on clinic no-shows, links between atazanavir and gall/kidney stones, anal sex and HIV among women, and the limits of echocardiography.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView: August 2012 (September 6, 2012)
    David Wohl, M.D., recaps recent, clinically relevant research focusing on viral suppression rates, HIV and hepatitis C treatment adherence levels, transmitted HIV drug resistance and the impact of community-wide HIV testing programs.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Clinical Developments of 2009 (February 2010)
    David Wohl, M.D., provides an illuminating, entertaining review of the research and news from 2009 that is most likely to change the clinical HIV/AIDS landscape.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Clinical Developments of 2008 (February 27, 2009)
    David Wohl, M.D., discusses earlier treatment initiation; key studies examining cardiovascular risk and abacavir; inflammatory biomarkers, coagulation biomarkers and mortality; and initial antiretroviral choices and how critical some of our newer medications are to the survival of patients with multidrug resistance.
    To read PDF, click here.
    In HIV JournalView, from TheBodyPRO.com
  • HIV JournalView (June 2008)
    David Wohl, M.D., discusses the real-world clinical impact of studies on: a new treatment for visceral fat accumulation; the rise and fall of abacavir; the latest twist in the HAART/heart saga; HAART's ability to improve renal function; similarities among genotypic resistance algorithms; the virologic impact of baseline NNRTI resistance; and the efficacy of "supersized" hepatitis B revaccination.
    In HIV JournalView, from TheBodyPRO.com
  • Top 10 HIV Clinical Developments of 2007 (March 2008)
    How are the landmark studies of 2007 likely to impact your clinical practice? If it's incisive analysis you seek, look no further than David Wohl, M.D.'s overview of the Top 10 HIV Clinical Developments of 2007. With his expert eye and trademark wit, Dr. Wohl takes you behind the data for an up-close look at what the numbers really mean.
    In HIV JournalView, from TheBodyPRO.com

    • VIEW ALL ARTICLES